公开(公告)号：EP3129051A1

公开(公告)日：2017-02-15

申请号：EP15720796.0

申请日：2015-04-08

Applicant: Prothena Biosciences Limited ,  F. Hoffmann-La Roche AG

Inventor： BARBOUR, Robin ,  GAMES-THIEL, Kate Dora ,  NIIJAR, Tarlochan S. ,  ZAGO, Wagner ,  MUNDIGL, Olaf ,  NIEWOEHNER, Jens ,  TIEFENTHALER, Georg

IPC: A61K39/395 ,  C07K16/18 ,  C07K16/46 ,  A61P25/16 ,  A61P25/28 ,  A61K39/00

CPC classification number: C07K16/2881 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/33 ,  C07K2319/74 ,  C12N5/12 ,  C12N2510/02 ,  G01N33/6896 ,  G01N2333/47 ,  G01N2800/28 ,  G01N2800/50

Abstract: Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).

Abstract translation: 本发明提供了包含单克隆抗体5C1和与血脑屏障受体的单价结合实体连接的相关抗体的血脑屏障穿梭。 5C1抗体结合α-突触核蛋白的残基118-126内的表位。 抗体可用于治疗和/或诊断突触核蛋白病，包括路易体病，如帕金森氏病，弥漫性路易体病（DLBD），阿尔茨海默氏病的路易体变体（LBV），阿尔茨海默病和帕金森病共病;以及 纯自主神经衰竭，以及多系统萎缩（MSA）。

公开(公告)号：EP3099807A1

公开(公告)日：2016-12-07

申请号：EP14830805.9

申请日：2014-12-17

Applicant: Valitacell Limited

Inventor： THOMPSON, Ben ,  JAMES, David ,  CLIFFORD, Jerry

IPC: C12P21/00 ,  G06F19/00

CPC classification number: G06N7/005 ,  C12N5/0018 ,  C12N5/0682 ,  C12N2503/00 ,  C12N2510/02

Abstract: A computer implemented method of predicting relative fed batch production titer of a panel of clonal producer cells derived from a single parental host cell population comprises the steps of assaying a level of growth of each clone in the presence and absence of one or more individual chemical cell stressors, comparing the level of growth of each clone in the presence and absence of the or each chemical cell stressor to provide a normalised production titer response for each clone in the or each stressed microenvironment, and inputting a clone-specific production titer response profile comprising the normalised production titer response for each clone in the or each stressed microenvironments into a computational model. The computational model is generated from production titer response profiles obtained from a calibration set of clones with known fed batch production titer, and is configured to output the predicted relative fed batch production titer of the panel of clonal cells.

Abstract translation: 预测从一个单一的亲本宿主细胞群体衍生的克隆的生产细胞的面板的相对补料分批生产滴度的一种计算机实现的方法，包括：检测在一个或多个单独的化学电池的存在和不存在各克隆生长的水平的步骤 应激物在的存在和不存在或各化学细胞应激物比较每个克隆的生长水平，以提供在每个克隆一个获救生产滴度响应或每个强调微环境，以及输入特定克隆生产滴度响应简档包括 在所述或每个各克隆获救生产滴度响应强调微环境进入的计算模型。 计算模型是从校准组具有已知滴度补料分批生产克隆获得的生产滴度响应谱产生，并且被配置成输出克隆细胞的面板的预测相对补料分批生产滴度。

公开(公告)号：EP2994491A4

公开(公告)日：2016-12-07

申请号：EP14795167

申请日：2014-05-09

Applicant: WHITEHEAD INST BIOMEDICAL RES

Inventor： LODISH HARVEY ,  PLOEGH HIDDE L ,  LEE HSIANG-YING ,  SHI JIAHAI ,  KUNDRAT LENKA ,  PISHESHA NOVALIA

IPC: C07K19/00 ,  C12N9/00 ,  C12N9/10

CPC classification number: A61K35/18 ,  A01K67/0275 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  C07K14/47 ,  C07K14/705 ,  C07K14/70582 ,  C12N5/0641 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/999 ,  C12N2506/11 ,  C12N2510/02

Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.

Abstract translation: 提供了如此制备的体外生产去核红细胞和去核红细胞的方法。 这种去核的红细胞可以表达可分离的表面蛋白质，其允许在分拣酶存在下进行表面修饰。 本文还描述了表面修饰的去核红细胞，例如与感兴趣的试剂缀合，例如肽，可检测标记或化学治疗剂，及其用于将试剂递送至受试者的用途。

公开(公告)号：EP3094735A1

公开(公告)日：2016-11-23

申请号：EP14821407.5

申请日：2014-12-09

Applicant: Amgen Inc.

Inventor： KANG, Sohye ,  HUANG, Chung-Jr ,  BARKHORDARIAN, Hedieh ,  BONDARENKO, Pavel ,  ZHANG, Zhongqi

IPC: C12P21/00 ,  C07K16/00 ,  C12N1/38 ,  C12N5/00

CPC classification number: C12P21/005 ,  C07K14/52 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/41 ,  C12N1/38 ,  C12N5/0682 ,  C12N2500/32 ,  C12N2500/33 ,  C12N2500/46 ,  C12N2500/90 ,  C12N2510/02 ,  C12N2521/00

Abstract: The present invention relates to a method for manipulating the high mannose glycoform content of recombinant glycoproteins by regulating ornithine metabolism during cell culture.

公开(公告)号：EP3094639A1

公开(公告)日：2016-11-23

申请号：EP15734830.1

申请日：2015-01-13

Applicant: Leszcyniecka, Magdalena ,  Shulga-Morskoy, Sergey

Inventor： Leszcyniecka, Magdalena ,  Shulga-Morskoy, Sergey

IPC: C07K1/00 ,  C12N5/02 ,  C12P21/00

CPC classification number: C12P21/02 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/41 ,  C12N2510/02 ,  G01N2440/00

Abstract: A method for optimizing post-translational modifications of recombinant proteins expressed in living cells is described. More particularly, a method for modulation of host proteins in living cells that control PTMs on recombinant proteins is described that has particularly useful applications in developing manufacturing process changes or in biosimilar development. The goal of this modulation is to produce a recipe for production of a recombinant protein in the new process or in the biosimilar that will produce a targeted PTM profile in the resulting protein product. In the method one or more modulators are selected, as from a modulator library, which affect the activity of host proteins. These modulators are added to media during production such that the resulting product matches the PTMs of the reference product. The ideal set of modulators and their concentrations are identified through a unique iterative process and the combined modulators and their concentrations constitute a recipe for growth media for the production of said recombinant protein. The methodology to obtain such a recipe described herein may then be used in many applications, such as optimizing new batches of recombinant protein drugs, developing biosimilar or bio-better drugs.

公开(公告)号：EP2561065B1

公开(公告)日：2016-11-09

申请号：EP11772796.6

申请日：2011-04-22

Applicant: Life Technologies Corporation

Inventor： BARRETT, Shawn ,  JACOBIA, Scott

IPC: C12N5/02 ,  C12N1/38 ,  C07K5/06 ,  C12N7/01 ,  C12P21/02

CPC classification number: C12N5/0018 ,  C12N5/005 ,  C12N2500/32 ,  C12N2501/998 ,  C12N2510/02 ,  C12P21/02

公开(公告)号：EP3083676A1

公开(公告)日：2016-10-26

申请号：EP14821859.7

申请日：2014-12-18

Applicant: Novartis AG

Inventor： JOSTOCK, Thomas ,  LAUX, Holger ,  RITTER, Anett

IPC: C07K16/00 ,  C12N5/00

CPC classification number: C07K16/00 ,  C07K2317/14 ,  C12N15/113 ,  C12N2310/14 ,  C12N2510/02 ,  C12N2511/00

Abstract: The disclosure pertains to novel eukaryotic cell suitable for recombinant production of a product of interest, wherein the effect of the expression product of an endogenous gene C12orf35 is impaired in said cell, thereby increasing their productivity when recombinantly expressing a polypeptide of interest. Furthermore, the present disclosure provides associated technologies wherein such host cells are used in recombinant production technologies.

Abstract translation: 本公开涉及适用于重组产生感兴趣的产物的新型真核细胞，其中所述细胞内内源基因C12orf35的表达产物的作用受损，从而在重组表达感兴趣的多肽时提高其生产力。 此外，本公开提供了其中这种宿主细胞用于重组生产技术的相关技术。

公开(公告)号：EP3042956A1

公开(公告)日：2016-07-13

申请号：EP14842086.2

申请日：2014-09-05

Applicant: University of Miyazaki ,  Fujita Health University ,  Perseus Proteomics Inc.

Inventor： MORISHITA Kazuhiro ,  KANEDA Kazuko ,  KUROSAWA Yoshikazu ,  KUROSAWA Gene ,  MITOMO Katsuyuki ,  KOUDA Katsushi ,  UKAI Yoshinori

IPC: C12N15/09 ,  A61K39/395 ,  A61P1/00 ,  A61P1/16 ,  A61P1/18 ,  A61P11/00 ,  A61P13/08 ,  A61P13/10 ,  A61P15/00 ,  A61P17/00 ,  A61P35/00 ,  A61P35/02 ,  C07K16/28 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08

CPC classification number: C07K16/2839 ,  A61K31/365 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C12N2510/02 ,  A61K2300/00

Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.

公开(公告)号：EP2994491A2

公开(公告)日：2016-03-16

申请号：EP14795167.7

申请日：2014-05-09

Applicant: The Whitehead Institute for Biomedical Research

Inventor： LODISH, Harvey ,  PLOEGH, Hidde, L. ,  LEE, Hsiang-Ying ,  SHI, Jiahai ,  KUNDRAT, Lenka ,  PISHESHA, Novalia

IPC: C07K19/00 ,  C12N9/00 ,  C12N9/10

CPC classification number: A61K35/18 ,  A01K67/0275 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  C07K14/47 ,  C07K14/705 ,  C07K14/70582 ,  C12N5/0641 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/999 ,  C12N2506/11 ,  C12N2510/02

Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.

公开(公告)号：EP1957630B1

公开(公告)日：2016-02-17

申请号：EP06847508.6

申请日：2006-12-06

Applicant: Amgen Inc.

Inventor： CROWELL, Christopher, K. ,  GRAMPP, Gustavo

IPC: C12N5/02 ,  C07K14/505

CPC classification number: C07K14/505 ,  C07K14/575 ,  C12N5/0018 ,  C12N2500/20 ,  C12N2500/32 ,  C12N2510/02 ,  C12P21/005

Abstract: Culture media comprising manganese and methods of culturing cells to improve sialysation and glycosylation of glycoproteins are provided.

Abstract translation: 提供了包含锰的培养基和培养细胞以改善糖蛋白的脱水和糖基化的方法。